CN107660207B - 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 - Google Patents

丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 Download PDF

Info

Publication number
CN107660207B
CN107660207B CN201680027202.2A CN201680027202A CN107660207B CN 107660207 B CN107660207 B CN 107660207B CN 201680027202 A CN201680027202 A CN 201680027202A CN 107660207 B CN107660207 B CN 107660207B
Authority
CN
China
Prior art keywords
buprenorphine
less
free base
acetate
blend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680027202.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107660207A (zh
Inventor
C·弗雷德里克·M·亨特利
埃里克·韦恩·卡泰斯托
黑尔格·阿尔弗雷德·赖施
阿尔沙纳·夏尔马
亚克·拉里·斯蒂米斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhodes Technologies Inc
Original Assignee
Rhodes Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies Inc filed Critical Rhodes Technologies Inc
Publication of CN107660207A publication Critical patent/CN107660207A/zh
Application granted granted Critical
Publication of CN107660207B publication Critical patent/CN107660207B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CN201680027202.2A 2015-03-10 2016-03-09 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法 Expired - Fee Related CN107660207B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
US62/131,114 2015-03-10
PCT/IB2016/051332 WO2016142877A1 (en) 2015-03-10 2016-03-09 Acetate salt of buprenorphine and methods for preparing buprenorphine

Publications (2)

Publication Number Publication Date
CN107660207A CN107660207A (zh) 2018-02-02
CN107660207B true CN107660207B (zh) 2020-09-29

Family

ID=55524412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680027202.2A Expired - Fee Related CN107660207B (zh) 2015-03-10 2016-03-09 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法

Country Status (19)

Country Link
US (6) US10406152B2 (enExample)
EP (1) EP3283490A1 (enExample)
JP (2) JP6660399B2 (enExample)
KR (2) KR20200045010A (enExample)
CN (1) CN107660207B (enExample)
AR (1) AR103902A1 (enExample)
AU (2) AU2016230750B2 (enExample)
BR (1) BR112017019357A2 (enExample)
CA (2) CA3104099A1 (enExample)
CO (1) CO2017009130A2 (enExample)
EA (1) EA201792014A1 (enExample)
IL (1) IL254384A0 (enExample)
MA (1) MA45902A (enExample)
MX (1) MX2017011606A (enExample)
NZ (1) NZ735736A (enExample)
PH (1) PH12017501641A1 (enExample)
SG (1) SG11201707350TA (enExample)
TW (2) TWI699367B (enExample)
WO (1) WO2016142877A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105247038B (zh) 2013-03-15 2021-08-27 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)的微生物及其制备和使用方法
CN112410379B (zh) 2013-11-04 2024-12-31 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物以及制备和使用所述前体的方法
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107614688B (zh) 2015-05-04 2023-02-28 小利兰·斯坦福大学托管委员会 产生苄基异喹啉生物碱(bia)前体的微生物及其制备和使用方法
JP7266966B2 (ja) 2015-05-08 2023-05-01 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー エピメラーゼ及びベンジルイソキノリンアルカロイドを産生する方法
WO2018075670A1 (en) 2016-10-18 2018-04-26 Antheia, Inc. Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
BR112020002050A2 (pt) 2017-08-03 2020-09-08 Antheia, Inc. epimerases engenheiradas alcaloides benzilisoquinolina e métodos de produção de alcaloides benzilisoquinolina
AR117426A1 (es) * 2018-05-11 2021-08-04 Alar Pharmaceuticals Inc Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina
CN120399912A (zh) 2019-03-08 2025-08-01 小利兰·斯坦福大学托管委员会 产生莨菪烷生物碱(ta)的非植物宿主细胞及其制备和使用方法
IL317873A (en) * 2022-06-24 2025-02-01 Alar Pharmaceuticals Inc Stable pharmaceutical composition of buprenorphine and method of preparation and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368409A2 (en) * 1988-11-10 1990-05-16 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of buprenorphine salts
US20110009633A1 (en) * 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the Enrichment of Buprenorphine using Chromatographic Techniques
CN104114161A (zh) * 2011-12-12 2014-10-22 Lts勒曼治疗系统股份公司 包含丁丙诺啡的经皮递送系统

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (enExample) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
BRPI0720088A2 (pt) 2006-12-11 2013-12-24 Alcon Res Ltd Fluoresceína substancialmente pura
EP2311498A4 (en) * 2008-08-05 2013-07-24 Medrx Co Ltd EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF
MX2013003587A (es) * 2010-09-30 2013-05-31 Nektar Therapeutics Conjugados de naloxol-polietilenglicol cristalinos.
JP6279547B2 (ja) 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
EP2941433B1 (en) * 2012-12-31 2019-08-07 Rhodes Technologies Process for preparing 7 -substituted 6 ,14 -ethenomorphinans and 7 -substituted 6 ,14 -ethanomorphinans
SG11201509218SA (en) 2013-06-04 2015-12-30 Lohmann Therapie Syst Lts Transdermal delivery system
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
CA3104099A1 (en) * 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368409A2 (en) * 1988-11-10 1990-05-16 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of buprenorphine salts
US20110009633A1 (en) * 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the Enrichment of Buprenorphine using Chromatographic Techniques
CN104114161A (zh) * 2011-12-12 2014-10-22 Lts勒曼治疗系统股份公司 包含丁丙诺啡的经皮递送系统

Also Published As

Publication number Publication date
TW202037597A (zh) 2020-10-16
MX2017011606A (es) 2017-10-26
US20190314364A1 (en) 2019-10-17
US20210046066A1 (en) 2021-02-18
US10874662B2 (en) 2020-12-29
MA45902A (fr) 2019-06-19
JP6660399B2 (ja) 2020-03-11
JP2020033359A (ja) 2020-03-05
WO2016142877A1 (en) 2016-09-15
EP3283490A1 (en) 2018-02-21
AU2016230750B2 (en) 2019-05-30
IL254384A0 (en) 2017-11-30
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
CO2017009130A2 (es) 2017-11-21
CA2977732A1 (en) 2016-09-15
NZ735736A (en) 2019-02-22
US9926329B2 (en) 2018-03-27
KR20200045010A (ko) 2020-04-29
CN107660207A (zh) 2018-02-02
PH12017501641A1 (en) 2018-02-12
US10406152B2 (en) 2019-09-10
AU2019203308A1 (en) 2019-05-30
US20180162866A1 (en) 2018-06-14
JP2018507882A (ja) 2018-03-22
AR103902A1 (es) 2017-06-14
US10278967B2 (en) 2019-05-07
EA201792014A1 (ru) 2018-01-31
CA3104099A1 (en) 2016-09-15
KR20170137738A (ko) 2017-12-13
BR112017019357A2 (pt) 2018-06-05
TW201639856A (zh) 2016-11-16
US20190298713A1 (en) 2019-10-03
US20170197975A1 (en) 2017-07-13
CA2977732C (en) 2021-02-23
TWI699367B (zh) 2020-07-21
AU2016230750A1 (en) 2017-10-12
US20180235955A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
CN107660207B (zh) 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
US10519176B2 (en) Crystalline forms
US9296756B2 (en) Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200929

Termination date: 20210309